ITM to supply its n.c.a. 177Lu for the clinical development of Y-mAbs’ GD2-SADA: 177Lu-DOTA complex for GD2+ solid tumors
The P-I study of GD2-SADA is expected to be planned for 2022. GD2-SADA: 177Lu-DOTA Complex, 2-step radioimmunotherapy that can be given as an IV inf. while 177Lu-DOTA Complex targets the prior administered tumor-binding Ab construct GD2-SADA & consists of chelator (DOTA) & ITM’s n.c.a. 177Lu to delivery therapeutic radiation of n.c.a. 177Lu to the tumor-site & kill malignant cells
N.c.a. 177Lu is a highly pure, market-approved form of the beta-emitting radioisotope 177Lu that has been used in multiple cancer treatments. It can be linked to a no. of tumor-specific targeting molecules for cancers
Ref: GlobalNewswire | Image: ITM
